Second chance for hepatitis c cure: new trial tests best retreatment

NCT ID NCT05248919

ENROLLING_BY_INVITATION Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people in Pakistan with hepatitis C who did not get cured by their first treatment. It compares two different lengths of treatment with the drug Epclusa (12 weeks vs 24 weeks) to see which works better. About 318 adults will take part, and the goal is to find the safest and most effective way to clear the virus in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sofosbuvir and Velpatasvir (Epclusa)
What this could lead to: If successful, this trial could identify the best retreatment strategy for people with hepatitis C who did not get cured by first-line therapy, potentially improving cure rates in this group.
What could go wrong: This is a relatively small, non-randomized study in one region of Pakistan, so results may not apply broadly. The treatments are already approved, so the main question is which duration works best, not a breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

Clinical trials unit

Karachi, Sindh, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.